Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Diabetes drug pioglitazone as potential preventive therapy for recurring strokes

Feb. 19, 2016

Ironwood reports phase Ia data on soluble sGC stimulator IW-1701

Feb. 19, 2016

Corvidia Therapeutics raises Series A financing, licenses lead compound from AstraZeneca

Feb. 19, 2016

FDA issues complete response letter for Zetia and Vytorin

Feb. 16, 2016

Renova Therapeutics and Lonza enter manufacturing agreement for RT-100

Feb. 16, 2016

XBiotech enters agreement regarding antibodies for cardiovascular diseases

Feb. 15, 2016

GlaxoSmithKline introduces Lp-PLA2 inhibitors

Feb. 11, 2016

Greenville Health System and Selah Genomics launch test for risk of sudden cardiac death

Feb. 4, 2016

Merck & Co. develops ROMK channel blockers

Feb. 4, 2016

Phase IIa topline results for AIR-001 in HFpEF; new HFN-supported study planned

Feb. 2, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...